Key result
GPIHBP1 C89F and G175R mutations cause severe hyperchylomicronemia by impairing membrane targeting and LPL binding.
Observational (n=376)
The identification of C89F and G175R mutations in GPIHBP1 highlights the critical role of this protein in triglyceride-rich lipoprotein metabolism and the mechanisms underlying severe hyperchylomicronemia.
Answers are grounded in this paper and cite their sources.
Advances GPIHBP1 variant research in hyperchylomicronemia; leaves open clinical screening utility pending larger validation studies.
CONTEXT: GPIHBP1 is a new endothelial binding site for lipoprotein lipase (LPL), the key enzyme for intravascular lipolysis of triglyceride-rich lipoproteins (TGRL). We have identified two new missense mutations of the GPIHBP1 gene, C89F and G175R, by systematic sequencing in a cohort of 376 hyperchylomicronemic patients without mutations on the LPL, APOC2, or APOA5 gene. OBJECTIVE: Phenotypic expression and functional consequences of these two mutations were studied. DESIGN: We performed clinical and genotypic studies of probands and their families. GPIHBP1 functional alterations were studied in CHO pgsA-745 transfected cells. RESULTS: Probands are an adult with a homozygous G175R mutation and a child with a hemizygous C89F neomutation and a deletion of the second allele. C89F mutation was associated with a C14F signal peptide polymorphism on the same haplotype. Both patients had resistant hyperchylomicronemia, low LPL activity, and history of acute pancreatitis. In CHO pgsA-745 cells, both G175R and C14F variants reduce the expression of GPIHBP1 at the cell surface. C89F mutation is responsible for a drastic LPL-binding defect to GPIHBP1. C14F may further potentiate C89F effect. CONCLUSIONS: The emergence of hyperchylomicronemia in the generation after a neomutation further establishes a critical role for GPIHBP1 in TGRL physiopathology in humans. Our results highlight the crucial role of C65-C89 disulfide bond in LPL binding by GPIHBP1 Ly6 domain. Furthermore, we first report a mutation of the hydrophobic C-terminal domain that impairs GPIHBP1 membrane targeting.
No takes yet. Share an insight, caveat, or question.
Charrière et al. (2011) conducted an observational in Severe Hyperchylomicronemia (n=376). GPIHBP1 C89F and G175R mutations was evaluated on Phenotypic expression and functional consequences. GPIHBP1 C89F and G175R mutations cause severe hyperchylomicronemia by impairing membrane targeting and LPL binding.
Synapse has enriched 10 related papers. Consider them for comparative context: